Patient characteristics
UPN . | Histology . | Disease status at ASCT . | Prior chemo . | OI after ASCT . | Status . |
|---|---|---|---|---|---|
| 202 | DLC | First rel | CHOP | None | CR 67 months |
| 203 | Mixed cellularity, HD | First rel | CHOP, Ifos/VP16, ESHAP | None | CR 61 months |
| 204 | ALC | First PR | CHOP, ESHAP | None | Relapse; died at 4 months |
| 208 | DLC | First CR | CHOP, ESHAP | Zoster | CR 59 months |
| 209 | Mixed cellularity HD | First rel | BOSE, ABVD, ESHAP | Hep C | CR 56 months |
| 400 | BL | Second CR | POG 8617, 9517, 9317 | None | Relapse; died at 4 months |
| 405 | DLC | First PR | CHOP, ESHAP + RTX | CMV viremia | CR 66 months |
| 406 | DLC | First CR | CHOP | None | CR 78 months |
| 407 | BL | Third CR | CHOP, Ifos/VP16, RTX, ESHAP | Pneumocystis, CMV retinitis | CR 60 months |
| 408 | DLC | First CR | CHOP | None | CR 24 months |
| 409 | DLC | First PR | CHOP, ESHAP | None | Died at D + 22 |
| 410 | BL | First PR | MBACOD, ESHAP + RTX | CMV viremia | CR 49 months |
| 411 | BL | First rel | CHOP, ESHAP, RTX | Zoster | CR 50 months |
| 412 | BL | First PR | CAV, Ara-C-MTX, CODOX-M | None | CR 40 months |
| 413 | DLC | First rel | CHOP, ESHAP + RTX | None | CR 43 months |
| 414 | DLC | Second rel | EPOCH, ESHAP + RTX, Cy/Tax | None | CR 19 months |
| 415 | DLC | First rel | CHOP, ESHAP, RTX | Pneumocystis, aspergillus | CR 22 months |
| 416 | BL | Second rel | CHOP, ESHAP + RTX | None | CR 20 months |
| 417 | DLC | First CR | EPOCH, CHOP | None | CR 20 months |
| 418 | ALC | First rel | CHOP + RTX, ICE | None | CR 6 months |
UPN . | Histology . | Disease status at ASCT . | Prior chemo . | OI after ASCT . | Status . |
|---|---|---|---|---|---|
| 202 | DLC | First rel | CHOP | None | CR 67 months |
| 203 | Mixed cellularity, HD | First rel | CHOP, Ifos/VP16, ESHAP | None | CR 61 months |
| 204 | ALC | First PR | CHOP, ESHAP | None | Relapse; died at 4 months |
| 208 | DLC | First CR | CHOP, ESHAP | Zoster | CR 59 months |
| 209 | Mixed cellularity HD | First rel | BOSE, ABVD, ESHAP | Hep C | CR 56 months |
| 400 | BL | Second CR | POG 8617, 9517, 9317 | None | Relapse; died at 4 months |
| 405 | DLC | First PR | CHOP, ESHAP + RTX | CMV viremia | CR 66 months |
| 406 | DLC | First CR | CHOP | None | CR 78 months |
| 407 | BL | Third CR | CHOP, Ifos/VP16, RTX, ESHAP | Pneumocystis, CMV retinitis | CR 60 months |
| 408 | DLC | First CR | CHOP | None | CR 24 months |
| 409 | DLC | First PR | CHOP, ESHAP | None | Died at D + 22 |
| 410 | BL | First PR | MBACOD, ESHAP + RTX | CMV viremia | CR 49 months |
| 411 | BL | First rel | CHOP, ESHAP, RTX | Zoster | CR 50 months |
| 412 | BL | First PR | CAV, Ara-C-MTX, CODOX-M | None | CR 40 months |
| 413 | DLC | First rel | CHOP, ESHAP + RTX | None | CR 43 months |
| 414 | DLC | Second rel | EPOCH, ESHAP + RTX, Cy/Tax | None | CR 19 months |
| 415 | DLC | First rel | CHOP, ESHAP, RTX | Pneumocystis, aspergillus | CR 22 months |
| 416 | BL | Second rel | CHOP, ESHAP + RTX | None | CR 20 months |
| 417 | DLC | First CR | EPOCH, CHOP | None | CR 20 months |
| 418 | ALC | First rel | CHOP + RTX, ICE | None | CR 6 months |
ALC indicates anaplastic large cell; HD, Hodgkin disease; BL, Burkitt lymphoma; DLC, diffuse large cell; ABVD, adriamycin, bleomycin, vincristine/vinblastine, dacarbazine; Ara-C/MTX, cytarabine, methotrexate; BOSE, bleomycin, oncovin, streptozocin, etoposide; CAV, cyclophosphamide, vincristine, adriamycin, CHOP, cyclophosphamide, adriamycin, vincristine, prednisone; CODOX-M, cyclophosphamide, vincristine, adriamycin, methotrexate; ESHAP, etoposide, cytarabine, platinol, solumedrol; RTX, rituxan; MBACOD, methotrexate, bleomycin, adriamycin, cyclophosphamide, vincristine, cytarabine, dexamethasone; POG 9317, ifosfamide, etoposide, methotrexate, cytarabine; POG 9517, ifosfamide, etoposide, methotrexate, cytarabine; POG 8617, cyclophosphamide, adriamycin, cytarabine; OI, opportunistic infection.